Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Johns Hopkins University
Age
18–80
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Age \>18 years \< 80 years with diagnosis of end stage renal disease and currently undergoing outpatient hemodialysis (HD) at one of the Johns Hopkins University-affiliated HD units
You may not be if
Age\<18or\>80years
History of non-adherence to prescribed HD treatment
Active drug or heavy alcohol use (defined as \> 4 drinks/day)
Pregnancy or breast feeding
Active infection (bacterial or viral) or clinically significant infections within the past three months (e.g. those requiring hospitalization, or as judged by the PI)
Active malignancy (with the exception of excised non-metastatic basal cell carcinoma or squamous cell carcinoma of the skin, or adequately treated pre- invasive cervical cancer in situ)
Unstable cardiovascular status (angina, arrhythmias, congestive heart failure etc...)
History of liver disease (as defined by a diagnosis of uncompensated cirrhosis) • History of lung disease (including moderate-severe chronic obstructive pulmonary disease, interstitial lung disease, or asthma)
Known hypersensitivity to yeast-derived products
Hemoglobin \< 10 g/dL and hematocrit \< 30%.
Abnormal white blood cell (WBC) count at baseline (\< 3 or \> 12 x 10 cells/mm )
Treatment with WBC growth factors (G-CSF or GM-CSF) or immunosuppressive medications (tacrolimus, cyclosporine, mycophenolate, azathioprine, corticosteroids, chlorambucil, cyclophosphamide) within 4 weeks of study (erythropoiesis-stimulating agents will be allowed)
Treatment with lithium within 4 weeks of study
Clareo Health | Sargramostim for Myeloid Dendritic Cell Deficiency
